Overview

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This 39-week, open label study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2360 study.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Celecoxib
Diclofenac
Lumiracoxib